|
Title |
Phase | PI | Category | |
| Treatment of multiple sclerosis with anti-CD154: a phase II double-blind partial cross-over clinical trial (IDEC). | Mechanistic | Kasper | monitoring | |
| Protocol for use of brain tumor tissue for research. | Monitor | Fadul | monitoring | |
|
A trial of a CD40 activated dendritic cell vaccine in patients with resected colorectal cancer. |
Phase II | Barth | vaccine/ monitoring | |
|
The effect of CNTO 1275 on the immune responses of peripheral blood cells from subjects with relapsing forms of multiple sclerosis (Centocor).
|
Mechanistic | Kasper | monitoring | |
|
Dose-escalation study of EMD 273066 administered with low-dose cyclophosphamide to subjects with epithelial cell adhesion molecule (EpCAM) positive advanced cancers.
|
Phase I | Ernstoff | cellular | |
|
Dose dependent induction of T regulatory cells by glatiramer acetate: a parallel mechanistic study to GA9016 (TEVA Pharmaceuticals)
|
Mechanistic | Kasper | monitoring | |
| Longitudinal study of mild cognitive Iimpairment and early Alzheimer’s disease. | Monitor | Saykin | cytokine | |
| Autologous PBSC and immunotherapy for myeloma | Phase III | Meehan | cellular/ cytokine | |
| Immune mobilization of autologous PBSC with IL-2 and GM-CSF | Phase III | Meehan | cytokine | |
| Immunologic evaluation of peripheral blood | Monitor | Ernstoff | monitoring | |
| Autologous tumor/DC vaccine + IL-2 & IFNα in renal cell cancer | Phase II | Ernstoff | vaccine/ cytokine | |
| Pre-clinical studies for development of a DC in GBM | Pilot | Fadul | vaccine | |
| IL-2 in lymphodepleted primed melanoma patients | Phase II | Ernstoff | cytokine | |
| Adjuvant intra-nodal autologous DC in GBM | Phase II | Fadul | vaccine | |
| Cryoablation as immunomodulator in breast cancer | Pilot | Barth | vaccine/ monitoring | |
|
VEGF blockade autologous DC, IL-2, and IFNa-2b in renal cell cancer |
Phase II | Ernstoff | vaccine/ cytokine | |
| Cellular immunoRx, after autologous PBST for myeloma | Phase II | Meehan | cellular | |
| Modulation of immune system by VEGF in GBM | Pilot | Fadul | antibody | |
| Melanoma and renal tumor tissue bank extension | Monitor | Ernstoff | monitoring | |
|
Immune endpoints in blood & BM myeloma and healthy subjects
|
Monitor | Meehan | monitoring | |
| Immunological effects of GM-CSF/vaccine in renal cell cancer and melanoma | Pilot | Ernstoff | vaccine/ cytokine | |
| Leukapheresis for immunological endpoints | Monitor | Ernstoff | monitoring | |
| GM-CSF in patients with prostate cancer | Pilot | Ernstoff | cytokine | |
| Bevacizumab + IL-2 in renal cell cancer | Phase II | Ernstoff | cytokine/ antibody | |
| Melacine plus IFNa-2b vs. IFNa-2b in melanoma | Phase III | Ernstoff | vaccine/ cytokine | |
|
Induction of T regulatory cells in relapsing-remitting multiple sclerosis following treatment with anti-CD52 (Campath 1-H; Genzyme)
|
Mechanistic | Kasper | cellular/ cytokine | |
|
Induction of T regulatory cells and the effect on B cells by IFNb-1b (Bayer) |
Mechanistic | Kasper | monitoring | |
|
The relationship between thymic activity, regulatory T-cells and functional immune status in organ transplantation with alemtuzumab (Campath-1H) pretreatment and tacrolimus monotherapy.
|
Pilot | Zuckerman | cellular | |
|
The effect of psychosocial and behaviorally-based interventions on biological outcomes of patients with an advanced cancer diagnosis.
|
Pilot | Bakitas | cellular/ cytokine | |
|
Evaluation of the effect of age and prior immunity on the response to live or inactivated seasonal influenza vaccines in children.
|
Pilot | Wright | cellular/ cytokine | |
| An open-label, dose-escalation, phase I study of the safety, tolerability and immunogenicity of the prime-boost regimen of the investigational 2012/13 seasonal influenza DNA vaccine followed by the 2012/2013 seasonal influenza trivalent inactivated vaccine (TIV) compared to TIV prime-TIV boost in children and adolescents ages 6-17 Years. |
Phase I |
Wright | cellular/ cytokine | |